Japan Clears First iPSC Therapies for Clinical Use
Two iPSC-derived cell therapies receive time-limited authorization following early clinical trials
-
1
Japan has granted conditional approval for two iPSC-derived therapies, marking a global regulatory first for this technology.
-
2
ReHeart is an iPSC-derived cardiomyocyte sheet for severe heart failure, aimed at patients with no conventional treatment options.
-
3
Amchepry is a dopaminergic neural progenitor cell therapy for Parkinson’s disease, showing promise in a small clinical trial.
-
4
The approvals allow for commercialization while additional safety and efficacy data are collected post-approval.
-
5
Both therapies have limited clinical evidence, having been tested in small early-stage trials with fewer than ten patients.
